CN1281241C - Medicine for treating chronic bronchitis and its preparation method - Google Patents
Medicine for treating chronic bronchitis and its preparation method Download PDFInfo
- Publication number
- CN1281241C CN1281241C CN 200410008134 CN200410008134A CN1281241C CN 1281241 C CN1281241 C CN 1281241C CN 200410008134 CN200410008134 CN 200410008134 CN 200410008134 A CN200410008134 A CN 200410008134A CN 1281241 C CN1281241 C CN 1281241C
- Authority
- CN
- China
- Prior art keywords
- semen
- volatile oil
- chronic bronchitis
- parts
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 206010006458 Bronchitis chronic Diseases 0.000 title claims abstract description 17
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 17
- 208000007451 chronic bronchitis Diseases 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title description 4
- 239000000341 volatile oil Substances 0.000 claims abstract description 27
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 8
- 238000004821 distillation Methods 0.000 claims abstract description 7
- 235000004347 Perilla Nutrition 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 229940126678 chinese medicines Drugs 0.000 abstract 2
- 244000144725 Amygdalus communis Species 0.000 abstract 1
- 235000011437 Amygdalus communis Nutrition 0.000 abstract 1
- 235000006463 Brassica alba Nutrition 0.000 abstract 1
- 244000140786 Brassica hirta Species 0.000 abstract 1
- 235000011371 Brassica hirta Nutrition 0.000 abstract 1
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 241000801118 Lepidium Species 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 235000020224 almond Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000010354 integration Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine prescription for treating chronic bronchitis, and a preparation method thereof, which is composed of six Chinese medicines, such as Chinese ephedra, almond, perilla fruit, white mustard seed, radish seed and pepperweed seed. The preparation method comprises the following steps: firstly, water is added to the six Chinese medicines, and volatile oil is extracted by distillation for 2 to 5 hours and collected by another container to be reserved; aqueous solution from which the volatile oil is extracted is filtered to be reserved; herb residues are decocted by adding water, extracted 1 to 5 times and 0.5 to 3.0 hours for each time, filtered, combined with the aqueous solution, concentrated to the thick paste of the relative density of 1.30 to 1.65 (50 to 85 DEG C), baked under the condition of 60 to 80 DEG C, crushed into fine powder, sieved 70 to 140-mesh powder, mixed evenly, sprayed into the volatile oil and encapsulated. The present invention has significant curative effects on chronic bronchitis and has no toxic side effect.
Description
Affiliated technical field the invention belongs to Chinese medicine, and exactly relating to a kind of is the Chinese patent medicine of the treatment chronic bronchitis of feedstock production with the Chinese herbal medicine.
The background technology chronic bronchitis is because infection or non-infective agent cause the chronic nonspecific inflammation of trachea, bronchial mucosa and surrounding tissue thereof.Clinical with cough, expectoration or with panting and the chronic process of outbreak repeatedly is a feature.Early symptom is slight, and how in the winter time outbreak is alleviated after the spring is warm; Late period, inflammation increased the weight of, and symptom exists all the year round, was regardless of season.The state of an illness is if slowly make progress, often can concurrent obstructive emphysema, even pulmonary hypertension, pulmonary heart disease, be a kind of commonly encountered diseases, frequently-occurring disease of serious harm human health, show according to China's findings of the survey, prevalence is about crowd's 3.82%, and the old people is about 15%, some the area in addition up to 20%-30%.Along with the aging and the atmospheric pollution of population, its morbidity increases day by day, has a strong impact on people's work capacity and quality of life, is classified as one of tackling key problem disease by WHO.
For primary disease, Western medicine is relievingd asthma based on antiinflammatory, eliminating phlegm and relieving cough, spasmolytic at present, but independent all fundamentally relieve chronic bronchitic cough, expectoration or with panting and the symptom performance of outbreak repeatedly, integrated application still has certain side effect except that not guaranteeing the curative effect of application.Chinese medicine is accumulating a large amount of rich experiences aspect the treatment chronic bronchitis, has stronger advantage, but in clinical application kind for many years, how with Xuanhua removing summer-heat or with giving consideration to both the incidental and fundamental, strengthening vital QI to eliminate pathogenic factors is main, pays attention to taking stopgap measures in treating both the principal and secondary aspects of a disease, though clinical effective, but the course of treatment is long, and the prognosis of disease process is slower.Chinese patent database by retrieval, the identical patent report that is used for the treatment of chronic bronchitis of Shang Weijian and this prescription.
Summary of the invention the objective of the invention is to overcome the weak point that exists in the above-mentioned technology, provide a kind of have suppress cough reaction, antiasthmatic effect, antagonism isolated tracheal smooth muscle spasm, eliminate the phlegm, antiinflammatory, oxygen lack resistant function and suppress the chronic bronchitis therapeutic agent of acetic acid twisting reaction.
The technical solution used in the present invention is in order to achieve the above object:
8～40 parts of 6～30 parts of Fructus Perillaes of 6～30 portions of Semen Armeniacae Amarums of Herba Ephedrae
5～20 parts of 8～40 parts of Semen Lepidii (Semen Descurainiae)s of 5～20 parts of Semen Raphanis of Semen Sinapis Albae
Above Six-element adds 2～6 times of water gagings, and the way of distillation was extracted volatile oil 2～5 hours, and device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 1～5 time, each 0.5～3.0 hour, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is the thick paste of 1.30～1.65 (50～85 ℃), under 60～80 ℃ condition, dry, be ground into fine powder, 70～140 orders that sieve, mixing, spray into above-mentioned volatile oil, incapsulate.
Advantage of the present invention:
1, the flavour of a drug of the present invention kind that all is in the state-promulgated pharmacopoeia to be recorded is nontoxic to human body.
2, the present invention comes from clinical practice for many years, uses decoction through hundreds of routine patients and observes, and finds that it has significant curative effect to chronic bronchitis, and any toxicity do not occur.
3, after the present invention improves and manufactures experimently into capsule, grouping controlled observation through 110 examples, find no matter it is alleviating clinical symptoms, the quality of life of improving patient still all has extraordinary effect for the improvement of clinical coherent detection index, effective percentage has been verified this side's safety, effective more than 92%.
Specific embodiment prescription of the present invention is:
8～40 parts of 6～30 parts of Fructus Perillaes of 6～30 portions of Semen Armeniacae Amarums of Herba Ephedrae
5～20 parts of 8～40 parts of Semen Lepidii (Semen Descurainiae)s of 5～20 parts of Semen Raphanis of Semen Sinapis Albae
Preparation method of the present invention is:
Above Six-element adds 2～6 times of water gagings, and the way of distillation was extracted volatile oil 2～5 hours, and device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 1～5 time, each 0.5～3.0 hour, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is the thick paste of 1.30～1.65 (50～85 ℃), under 60～80 ℃ condition, dry, be ground into fine powder, 70～140 orders that sieve, mixing, spray into above-mentioned volatile oil, incapsulate.
Embodiment 1:
Herba Ephedrae 30g Semen Armeniacae Amarum 6g Fructus Perillae 8g
Semen Sinapis Albae 5g Semen Raphani 8g Semen Lepidii (Semen Descurainiae) 5g
Preparation method of the present invention is:
Above Six-element adds 2～6 times of water gagings, and the way of distillation was extracted volatile oil 2 hours, and device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 1～5 time, each 0.5 hour, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is the thick paste of 1.30～1.65 (50～85 ℃), under 60 ℃ condition, dry, be ground into fine powder, 70～140 orders that sieve, mixing, spray into above-mentioned volatile oil, incapsulate.
Embodiment 2
Herba Ephedrae 6g Semen Armeniacae Amarum 30g Fructus Perillae 40g
Semen Sinapis Albae 20g Semen Raphani 40g Semen Lepidii (Semen Descurainiae) 20g
Compounding method of the present invention is:
Above Six-element adds 2～6 times of water gagings, and the way of distillation was extracted volatile oil 3 hours, and device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 2～5 times, each 1.5 hours, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is the thick paste of 1.30～1.65 (50～85 ℃), under 70 ℃ condition, dry, be ground into fine powder, 70～140 orders that sieve, mixing, spray into above-mentioned volatile oil, incapsulate.
Embodiment 3
Herba Ephedrae 20g Semen Armeniacae Amarum 20g Fructus Perillae 30g
Semen Sinapis Albae 12g Semen Raphani 30g Semen Lepidii (Semen Descurainiae) 12g
Compounding method of the present invention is:
Above Six-element adds 2～6 times of water gagings, and the way of distillation was extracted volatile oil 5 hours, and device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 2～5 times, each 3.0 hours, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is the thick paste of 1.30～1.65 (50～85 ℃), under 80 ℃ condition, dry, be ground into fine powder, 70～140 orders that sieve, mixing, spray into above-mentioned volatile oil, incapsulate.
Characteristics of the present invention are that this medicament causes the mice strong aqua ammonia and coughs, the Cavia porcellus citric acid is caused to cough all can make the cough latent period significant prolongation, and the cough number of times significantly descends.Compare P＜0.05 with matched group.And Cavia porcellus asthma had significant antiasthmatic effect, and can resist the guinea-pig isolated tracheal smooth muscle spasm due to the histamine phosphate, compare P＜0.001 with matched group.
Another characteristics of the present invention are that this product can significantly increase the phenol red excretion amount of mice, reduce xylol and cause the swelling degree that auricle edema and Ovum Gallus domesticus album cause foot swelling, significantly suppress the acetic acid twisting reaction, compare with matched group to reduce to reach 50.5%.
A kind of clinical drug grouping controlled observation 110 routine results that treat chronic bronchitis
1, clinical data
The present invention is in Shanxi Chinese medicine academy, the clinical trial of first Affiliated Hospital of Mountain Western Medicine S University:
During clinical case adopts, Western medicine diagnose, differential diagnosis in tcm.Diagnostic criteria is with reference in November, 1979 whole nation chronic bronchitis clinical speciality meeting revised standard and State Administration of Traditional Chinese Medicine's " disease of tcm diagnosis criterion of therapeutical effect ", and the differential diagnosis in tcm standard is carried out according to " new Chinese medicine clinical research guideline " chronic bronchitis medicine typing principle.
All Chinese and western medicine diagnostic criteria and differential diagnosis in tcm standards of meeting, the case of the course of disease≤3 day.
Treatment group: a kind of medicine (capsule) for the treatment of chronic bronchitis 3/time every days three times
Matched group: GUILONG KECHUANNING JIAONANG 5/time every days three times
Every group is all carried out efficacy evaluation behind treatment 10d.
Difference (P＜0.05) that there are no significant aspect case source, sex age, the course of disease, cardinal symptom sign, auxiliary examination before two groups of treatments has comparability.
Observe the improvement of symptom before and after the treatment, sign integration, and the variation of chest X-ray, pulmonary function, and observe and have no adverse reaction.
2, criterion of therapeutical effect and therapeutic effect
Efficacy assessment standard according to relevant chronic bronchitis in " new Chinese medicine clinical research guideline " divides clinic control, produce effects, effective and invalid 4 classes.
Therapeutic index n=(the integration one treatment back integration/preceding integration of treatment * 100% before the treatment)
Clinic control: 〉=95%
Produce effects: 〉=70%
Effectively: 〉=30%
Invalid:＜30%
Two groups of therapeutic outcomes see the following form:
Table 1: two groups of curative effects relatively
| Group | The example number | Clinic control | Produce effects | Effectively | Invalid | Effective percentage |
| Treatment group matched group | 70 40 | 28 11 | 21 6 | 16 14 | 5 9 | 92.8％ 77.5％ |
As shown in Table 1: relatively there were significant differences (P＜0.01) for treatment group and matched group
Table 2: pulmonary function comparison before and after the treatment (X ± s)
| Group | The example number | Vc | FEV1(％) | MBC |
| The treatment group | 36 | Treat preceding 86.8 ± 17.5 and treat back 98.2 ± 23.1 ** | 64.2±15.2 74.4±11.2 ** | 68.6±18.1 85.4±18.8 ** |
| Matched group | 19 | Treat preceding 83.6 ± 18.1 and treat back 88.3 ± 17.1 * | 65.6±16.1 69.8±11.2 * | 67.9±17.3 75.2±17.4 * |
As shown in Table 2: relatively preceding with the treatment of this group:
*P＜0.01;
*P＜0.05
Claims (2)
1, a kind of medicine for the treatment of chronic bronchitis is characterized in that material medicine is as follows:
8～40 parts of 6～30 parts of Fructus Perillaes of 6～30 portions of Semen Armeniacae Amarums of Herba Ephedrae
5～20 parts of 8～40 parts of Semen Lepidii (Semen Descurainiae)s of 5～20 parts of Semen Raphanis of Semen Sinapis Albae.
2, the preparation method of the treatment chronic bronchitis medicine of claim 1, it is characterized in that: get Herba Ephedrae, Semen Armeniacae Amarum, Fructus Perillae, Semen Sinapis Albae, Semen Raphani, Semen Lepidii (Semen Descurainiae) Six-element, add 2～6 times of water gagings, the way of distillation was extracted volatile oil 2～5 hours, device is collected volatile oil in addition, and is standby; Aqueous solution behind the extraction volatile oil filters, and is standby; Medicinal residues decoct with water and extract 1～5 time, each 0.5～3.0 hour, filter, merge with above-mentioned aqueous solution, being concentrated into relative density is 1.30～1.65, measure down for 50～85 ℃, under 60～80 ℃ condition, dry, be ground into fine powder, 70～140 orders sieve, mixing sprays into above-mentioned volatile oil, incapsulates.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410008134 CN1281241C (en) | 2004-03-05 | 2004-03-05 | Medicine for treating chronic bronchitis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410008134 CN1281241C (en) | 2004-03-05 | 2004-03-05 | Medicine for treating chronic bronchitis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1663582A CN1663582A (en) | 2005-09-07 |
| CN1281241C true CN1281241C (en) | 2006-10-25 |
Family
ID=35035010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410008134 Expired - Lifetime CN1281241C (en) | 2004-03-05 | 2004-03-05 | Medicine for treating chronic bronchitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1281241C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306424A (en) * | 2014-07-22 | 2015-01-28 | 河南中医学院 | Application of semen lepidii fatty oil in preparing drugs capable of suppressing cough, dispelling phlegm and calming panting |
| CN105125973A (en) * | 2015-10-16 | 2015-12-09 | 张永波 | Traditional Chinese medicine preparation for treating infantile bronchitis |
| CN106038975A (en) * | 2016-08-01 | 2016-10-26 | 郑金鹏 | Traditional Chinese medicine composition having function of suppressing cough and preparation method and application of traditional Chinese medicine composition |
-
2004
- 2004-03-05 CN CN 200410008134 patent/CN1281241C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1663582A (en) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101564458B (en) | Application of Chinese medicinal composition in preparing medicament for treating bronchitis | |
| CN100475263C (en) | Medicine for treating chronic obstructive lung disease and preparation method thereof | |
| CN1281241C (en) | Medicine for treating chronic bronchitis and its preparation method | |
| US20090130231A1 (en) | Pharmaceutical formulation for treating tinea of feet and hands and preparation thereof | |
| WO2021042275A1 (en) | Traditional chinese medicine composition for treating osteoarthritis | |
| CN114767824B (en) | Preparation for treating laryngeal cough and preparation method thereof | |
| CN104706690A (en) | Ching's briggsia extract and application thereof in medicament for treating gastric ulcer | |
| CN101239175B (en) | Lung comforting plaster and preparation thereof | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN109939171B (en) | Traditional Chinese medicine composition for treating cough after infection and application thereof | |
| CN101062255A (en) | Decoction for treating asthma and so on | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN106822733B (en) | Ointment for treating precancerous lesion of chronic atrophic gastritis and preparation method thereof | |
| CN102357181A (en) | Traditional Chinese medicine composition for treating cough and preparation method thereof | |
| CN1235620C (en) | Medicine for treating cerebral thrombosis and its preparing process | |
| CN1943691A (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| WO2021042276A1 (en) | Combination drug for treating osteoarthritis | |
| CN113274470B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia | |
| CN1173731C (en) | Chinese medicine composite for curing chronic hepatitis B, fibrosis of liver and for curing SARS | |
| CN1579434A (en) | Chaihuang Tonic and its preparation method | |
| CN1853696A (en) | Medicine for treating coronary heart disease and preparation thereof | |
| CN1160109C (en) | Medicine for treating wind-heat type common cold and its preparing process | |
| CN104225034B (en) | Application of composition in preparing medicine for treating non-infectious urethral syndrome | |
| CN1475261A (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN101991730A (en) | Traditional Chinese medicine compound preparation for treating bronchial asthma and resisting recurrence and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20081226 Address after: Shanxi Tunliu Changzhi hi tech Industrial Zone Shanxi Kaiyuan Pharmaceutical Co., Ltd. Patentee after: Shanxi Kaiyuan Pharmaceutical Co.,Ltd. Address before: Beijing City, Haidian District landianchang road 10F-1023 No. 25 Newton office room Patentee before: Luo Chunxiu |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANXI KAIYUAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LUO CHUNXIU Effective date: 20081226 |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHANXI ZHENDONG KAIYUAN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHANXI KAIYUAN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 046108 Tunliu Kaiyuan hi tech Industrial Zone, Changzhi, Shanxi province Shanxi Kaiyuan Pharmaceutical Co., Ltd. Patentee after: SHANXI ZHENDONG KAIYUAN PHARMACEUTICAL Co.,Ltd. Address before: 046108 Tunliu Kaiyuan hi tech Industrial Zone, Changzhi, Shanxi province Shanxi Kaiyuan Pharmaceutical Co., Ltd. Patentee before: Shanxi Kaiyuan Pharmaceutical Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANXI ZHENDONG PHARMACEUTICAL CO., LTD. BEIJING Z |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100622 Address after: 046108 Tunliu Kaiyuan hi tech Industrial Zone, Changzhi, Shanxi province Shanxi Kaiyuan Pharmaceutical Co., Ltd. Co-patentee after: SHANXI ZHENDONG PHARMACEUTICAL Co.,Ltd. Patentee after: SHANXI ZHENDONG KAIYUAN PHARMACEUTICAL Co.,Ltd. Co-patentee after: BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 046108 Tunliu Kaiyuan hi tech Industrial Zone, Changzhi, Shanxi province Shanxi Kaiyuan Pharmaceutical Co., Ltd. Patentee before: SHANXI ZHENDONG KAIYUAN PHARMACEUTICAL Co.,Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 046000 Tunliu Kangzhuang high tech Industrial Park, Changzhi City, Shanxi Province Patentee after: Shanxi Zhendong wuhetang Pharmaceutical Co.,Ltd. Patentee after: SHANXI ZHENDONG PHARMACEUTICAL Co.,Ltd. Patentee after: BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 046108 Shanxi Kaiyuan Pharmaceutical Co.,Ltd. Patentee before: SHANXI ZHENDONG KAIYUAN PHARMACEUTICAL Co.,Ltd. Patentee before: SHANXI ZHENDONG PHARMACEUTICAL Co.,Ltd. Patentee before: BEIJING ZHENDONG GUANGMING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061025 |
|
| CX01 | Expiry of patent term |